Skip to content
Peptigraph home

Ecnoglutide Phase 2 trial (NCT05111912)

A Phase 2, Open-label, Randomised, Dose-Finding Study of XW003, Once-Weekly Human Glucagon-Like Peptide 1 Analogue, Compared With Once-Daily Liraglutide 3 mg in Adult Participants With Obesity

Registry record checked

At a glance

Phase
Phase 2
Status
Completed
Enrolment
206
actual
Start
30 Nov 2021 (actual)
Primary completion
16 Nov 2022 (actual)
Sponsor
Sciwind Biosciences APAC CO Pty. Ltd.
Design

Arms and doses

NCT05111912 study arms
ArmTypeInterventionsDescription
Cohort AExperimentalDrug: XW003Participants will follow a fixed up-titration scheme. For XW003 groups, the dose will be up-titrated to 1.2, 1.8, or 2.4 mg once weekly starting with 0.2 mg in dose increments of 0.2, 0.4, 0.6, or 0.8 mg. In order to mitigate the dose-related side effects, liraglutide is up-titrated over 4 weeks to the maintenance dose, 3.0 mg once daily.
Cohort BExperimentalDrug: XW003Participants will follow a fixed up-titration scheme. For XW003 groups, the dose will be up-titrated to 1.2, 1.8, or 2.4 mg once weekly starting with 0.2 mg in dose increments of 0.2, 0.4, 0.6, or 0.8 mg. In order to mitigate the dose-related side effects, liraglutide is up-titrated over 4 weeks to the maintenance dose, 3.0 mg once daily.
Cohort CExperimentalDrug: XW003Participants will follow a fixed up-titration scheme. For XW003 groups, the dose will be up-titrated to 1.2, 1.8, or 2.4 mg once weekly starting with 0.2 mg in dose increments of 0.2, 0.4, 0.6, or 0.8 mg. In order to mitigate the dose-related side effects, liraglutide is up-titrated over 4 weeks to the maintenance dose, 3.0 mg once daily.
Cohort DActive comparatorDrug: SaxendaDose titration Saxenda (from 0.6 mg to 3.0 mg liraglutide once daily), should take place during the first 4 weeks after randomisation as described: Dose Escalation Schedule of Reference Product (Saxenda). All participants assigned to the open-labeled control group should aim to reach the final target dose of 3.0 mg liraglutide once daily.
Endpoints

Primary endpoint

NCT05111912 primary outcomes
MeasureTime frame
Percentage change in participants body weight (%) from the BaselineWeek 26
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT05111912 secondary outcomes
MeasureTime frame
Proportions of participants with body weight loss ≥5%, ≥10% and ≥15% of the BaselineWeek 26
Absolute change in body weight (kg) of participantsWeek 26
Changes in waist circumference and hip circumference (cm) in participantsWeek 26
Change in BMI in participantsWeek 26
Change in fasting plasma glucose (FPG)Week 26
Change in fasting serum insulinWeek 26
Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)Week 26
Changes in fasting lipids (triglyceride, low-density lipoprotein [LDL], and high-density lipoprotein [HDL])Week 26
Number and severity of treatment-emergent adverse events (TEAEs)Week 26
Number and severity of new and ongoing gastrointestinal (GI) disorder (nausea, vomiting, diarrhea, and constipation) events by weekWeek 26
Vital signs - participants' blood pressure changeWeek 26
Vital signs - participants' pulse rate changeWeek 26
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
70 Years
Results

Results

No results posted on ClinicalTrials.gov as of 2 Oct 2026.

Sources

  1. 1A Phase 2, Open-label, Randomised, Dose-Finding Study of XW003, Once-Weekly Human Glucagon-Like Peptide 1 Analogue, Compared With Once-Daily Liraglutide 3 mg in Adult Participants With ObesityClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.